Ricevi le ultime notizie sulle azioni Emergent BioSolutions con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di EBS

Ultime notizie per

EMERGENT BIOSOLUTIONS INC

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

Press Releases

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Earnings

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

News

Health Care

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Emergent BioSolutions to Participate in Upcoming Investor Conferences

General

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Contracts

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Absci

ADC Therapeutics

Astria Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

enGene Holdings

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

I-MAB

Inhibrx Biosciences

Korro Bio

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Ocugen

Organogenesis Holdings

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

RAPT Therapeutics

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Solid Biosciences

Verastem

XOMA Royalty

HC Wainwright & Co.

Benchmark

Rodman & Renshaw

Chardan Capital

Screenshot 2025-03-19 at 8.55.22 PM

Biotech

BVNKF

TNXP

As Mpox Cases Spread Around The World, Tonix Pharmaceuticals&#39; Single-Dose Vaccine TNX-801 Has Potential To Slow The Spread

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Comments

Emergent BioSolutions Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO